Current Report Filing (8-k)
November 07 2019 - 5:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 6th, 2019
CANNABICS
PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
333-192759
|
20-3373669
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer No.)
|
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices
and Zip Code)
877 424-2429
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐ Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on
which registered
|
Common Stock, par value $0.0001 per share
|
|
CNBX
|
|
OTCQB
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
4.01
|
Changes in Registrant's Certifying Accountant
|
Cannabics Pharmaceuticals Inc. (the
“Company”) has dismissed BDO Ziv Haft (“Former Accounting Firm”) as its independent registered public accounting
firm, effective as of November 6th, 2019. As described in Item 4.01(a) below, the change in independent registered
public accounting firm is not the result of any disagreement with the Former Accounting Firm. The Board made the decision to dismiss
the Former Accounting Firm acting under authority delegated to it and the Board of Directors approved the same on November 6th,
2019. On the same date, the Company engaged Weinstein International CPA, 17 Kissufim St, Jerusalem, Israel (“the new accounting
firm”) as its new independent accounting firm as of and for the year ended August 31st, 2019.
During the years ended August 31, 2018
and 2017, and through the Dismissal Date, there were (i) no disagreements between the Company and BDO Ziv Haft on any matter of
accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement, if not
resolved to the satisfaction of BDO Ziv Haft, would have caused them to make reference thereto in their reports on the consolidated
financial statements for such years, and (ii) no “reportable events” as that term is defined in Item 304(a)(1)(v) of
Regulation S-K.
The Company has not consulted with the
New Accounting Firm during our two most recent fiscal years or during any subsequent interim period prior to its appointment as
New Accounting Firm regarding either (i) the application of accounting principles to a specified transaction, either completed
or proposed; or the type of audit opinion that might be rendered on our financial statements, and neither a written report was
provided to us nor oral advice was provided that the New Accounting Firm concluded was an important factor considered by the Company
in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject
of disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (within
the meaning of Item 304(a)(1)(v) of Regulation S-K).
The Company has requested that the Former
Accounting Firm furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with
the above statement. A copy of the letter from the Former Accounting Firm is attached hereto as Exhibit 16.1 to this Form 8-K
Item
9.01
|
Financial Statements & Exhibits
|
(d) Exhibits
3.1 Board Resolution
16.1 Letter from BDO Ziv Haft
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Cannabics Pharmaceuticals Inc.
|
|
|
|
By:
|
/s/ Eyal Barad
|
|
|
Eyal Barad
Director, CEO
|
Date:
November 7, 2019
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Sep 2023 to Sep 2024